[
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients",
        "summary": "Listen to a soundcast of the 12.18.2024 FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-ryoncil-remestemcel-l-rknd-steroid-refractory-acute-graft",
        "published": "Fri, 17 Jan 2025 13:10:28 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy",
        "summary": "FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-bizengri-zenocutuzumab-zbco-treatment-adults-advanced",
        "published": "Mon, 30 Dec 2024 09:28:30 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma",
        "summary": "Listen to a soundcast of the 8.2.2024 FDA approval of Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-tecelra-afamitresgene-autoleucel-unresectable-or-metastatic",
        "published": "Mon, 18 Nov 2024 13:44:38 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for unresectable advanced or metastatic malignant pleural mesothelioma",
        "summary": "Listen to a soundcast of the 9.17.2024 FDA approval of Keytruda (pembrolizumab) for unresectable advanced or metastatic malignant pleural mesothelioma.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-keytruda-pembrolizumab-unresectable-advanced-or-metastatic",
        "published": "Thu, 14 Nov 2024 11:34:15 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approvals of Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors and Krazati (adagrasib) for KRAS G12C-mutated colorectal cancer",
        "summary": "Listen to a soundcast of the June 13, 2024, and June 21, 2024, Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors&nbsp;and Krazati (adagrasib)&nbsp;for&nbsp;KRAS G12C-mutated colorectal cancer.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-augtyro-repotrectinib-ntrk-gene-fusion-positive-solid-tumors",
        "published": "Fri, 16 Aug 2024 14:22:19 EDT",
        "keywords": [
            "KRAS"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Retevmo (selpercatinib) for advanced or metastatic RET fusion-positive thyroid cancer",
        "summary": "Listen to a soundcast of the May 29, 2024, FDA approval of Retevmo (selpercatinib) for patients with advanced or metastatic&nbsp;RET&nbsp;fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-retevmo-selpercatinib-advanced-or-metastatic-ret-fusion",
        "published": "Tue, 02 Jul 2024 07:02:09 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Ojemda (tovorafenib) for relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation",
        "summary": "Listen to a soundcast of the April 23, 2024, FDA approval of Ojemda (tovorafenib) for relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-ojemda-tovorafenib-relapsed-or-refractory-pediatric-low-grade",
        "published": "Mon, 17 Jun 2024 11:00:47 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-positive solid tumors",
        "summary": "Listen to a soundcast of the April 5, 2024, FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki)&nbsp;for unresectable or metastatic HER2-positive solid tumors.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-enhertu-fam-trastuzumab-deruxtecan-nxki-unresectable-or",
        "published": "Fri, 26 Apr 2024 14:29:03 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of OGSIVEO (nirogacestat) for adult patients with progressing desmoid tumors who require systemic treatment",
        "summary": "Listen to a soundcast of the November 27, 2023 FDA approval of OGSIVEO (nirogacestat) for adult patients with progressing desmoid tumors who require systemic treatment.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-ogsiveo-nirogacestat-adult-patients-progressing-desmoid-tumors",
        "published": "Mon, 08 Jan 2024 13:02:10 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Augtyro (repotrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer",
        "summary": "FDA D.I.S.C.O. Burst Edition: FDA approval of Augtyro (repotrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-augtyro-repotrectinib-locally-advanced-or-metastatic-ros1",
        "published": "Fri, 05 Jan 2024 14:23:58 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Fruzaqla (fruquintinib) for adult patients with metastatic colorectal cancer",
        "summary": "FDA D.I.S.C.O. Burst Edition: FDA approval of Fruzaqla (fruquintinib) for adult patients with metastatic colorectal cancer",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-fruzaqla-fruquintinib-adult-patients-metastatic-colorectal",
        "published": "Fri, 05 Jan 2024 10:22:38 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Tibsovo (ivosidenib) for patients with relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 mutation",
        "summary": "FDA D.I.S.C.O. Burst Edition: FDA approval of Tibsovo (ivosidenib) for patients with relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 mutation",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-tibsovo-ivosidenib-patients-relapsed-or-refractory",
        "published": "Mon, 20 Nov 2023 14:18:04 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer",
        "summary": "Listen to a soundcast of the May 31, 2023, FDA approval of Lynparza&nbsp;(olaparib), with&nbsp;abiraterone and prednisone,&nbsp;for BRCA-mutated metastatic castration-resistant prostate cancer.\u201d",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-lynparza-olaparib-abiraterone-and-prednisone-brca-mutated",
        "published": "Thu, 13 Jul 2023 10:01:49 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma",
        "summary": "Listen to a soundcast of the May 19, 2023, FDA approval of Epkinly (epcoritamab-bysp)&nbsp;for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-epkinly-epcoritamab-bysp-relapsed-or-refractory-diffuse-large-b",
        "published": "Wed, 21 Jun 2023 08:54:07 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Polivy (polatuzumab vedotin-piiq) for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma",
        "summary": "Listen to a soundcast of the April 19, 2023, FDA approval of Polivy (polatuzumab vedotin-piiq) for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-polivy-polatuzumab-vedotin-piiq-previously-untreated-diffuse",
        "published": "Wed, 07 Jun 2023 13:52:48 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Omisirge (omidubicel-onlv) to reduce time to neutrophil recovery and infection in patients with hematologic malignancies",
        "summary": "Listen to a soundcast of the April 17, 2023, FDA approval of Omisirge (omidubicel-onlv) to reduce time to neutrophil recovery and infection in patients with hematologic malignancies.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-omisirge-omidubicel-onlv-reduce-time-neutrophil-recovery-and",
        "published": "Thu, 25 May 2023 10:10:34 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Padcev (enfortumab vedotin-ejfv) with Keytruda (pembrolizumab) for locally advanced or metastatic urothelial carcinoma",
        "summary": "Listen to a soundcast of the April 19, 2023, FDA approval of Padcev (enfortumab vedotin-ejfv) with&nbsp;Keytruda (pembrolizumab) for locally advanced or metastatic urothelial carcinoma.\u201d",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-padcev-enfortumab-vedotin-ejfv-keytruda-pembrolizumab-locally",
        "published": "Wed, 03 May 2023 16:03:06 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Zynyz (retifanlimab-dlwr) for metastatic or recurrent locally advanced Merkel cell carcinoma",
        "summary": "Lsten to a soundcast of the March 22, 2023 FDA approval of Zynyz (retifanlimab-dlwr) for metastatic or recurrent locally advanced Merkel cell carcinoma.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-zynyz-retifanlimab-dlwr-metastatic-or-recurrent-locally",
        "published": "Thu, 20 Apr 2023 09:46:15 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Tafinlar (dabrafenib) with Mekinist (trametinib) for pediatric patients with low-grade glioma with a BRAF V600E mutation",
        "summary": "Listen to a soundcast of the March 16, 2023, FDA approval of Tafinlar (dabrafenib) for pediatric patients with low-grade glioma with a BRAF V600E mutation",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-tafinlar-dabrafenib-mekinist-trametinib-pediatric-patients-low",
        "published": "Thu, 06 Apr 2023 08:56:48 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Verzenio (abemaciclib) with endocrine therapy for patients with HR-positive, HER2-negative, node-positive, early breast cancer",
        "summary": "Listen to a soundcast of the March 3, 2023, FDA approval of Verzenio (abemaciclib)&nbsp;with endocrine therapy for patients with HR-positive, HER2-negative, node-positive, early breast cancer.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-verzenio-abemaciclib-endocrine-therapy-patients-hr-positive",
        "published": "Fri, 24 Mar 2023 09:55:53 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Jemperli (dostarlimab-gxly) for dMMR endometrial cancer",
        "summary": "Listen to a soundcast of the February 9, 2023, FDA approval of Jemperli&nbsp;(dostarlimab-gxly) for mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following a prior platinum-containing regimen.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-jemperli-dostarlimab-gxly-dmmr-endometrial-cancer",
        "published": "Tue, 07 Mar 2023 14:18:33 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Trodelvy (sacituzumab govitecan-hziy) for HR-positive breast cancer",
        "summary": "Listen to a soundcast of the February 3, 2023, FDA approval of Trodelvy (sacituzumab govitecan-hziy) for HR-positive breast cancer.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-trodelvy-sacituzumab-govitecan-hziy-hr-positive-breast-cancer",
        "published": "Wed, 01 Mar 2023 11:45:13 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) as adjuvant treatment for non-small cell lung cancer",
        "summary": "Listen to a soundcast of the January 26, 2023, FDA approval of Keytruda (pembrolizumab)&nbsp;as&nbsp;adjuvant treatment for non-small cell lung cancer",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-keytruda-pembrolizumab-adjuvant-treatment-non-small-cell-lung",
        "published": "Wed, 01 Mar 2023 11:43:13 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approvals of Tecentriq (atezolizumab) for unresectable or metastatic alveolar soft part sarcoma, and Krazati (adagrasib) for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer",
        "summary": "Listen to a soundcast of the December 9 and 12, 2022, FDA approvals of Tecentriq (atezolizumab) for unresectable or metastatic alveolar soft part sarcoma, and Krazati (adagrasib) for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer\u201d",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-tecentriq-atezolizumab-unresectable-or-metastatic-alveolar",
        "published": "Mon, 23 Jan 2023 11:54:30 EST",
        "keywords": [
            "KRAS"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Adstiladrin (nadofaragene firadenovec-vncg) for patients with high-risk Bacillus Calmette-Gu\u00e9rin unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors",
        "summary": "Listen to a soundcast of the December 16, 2022, FDA approval of Adstiladrin (nadofaragene firadenovec-vncg) for patients with high-risk Bacillus Calmette-Gu\u00e9rin unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-adstiladrin-nadofaragene-firadenovec-vncg-patients-high-risk",
        "published": "Fri, 20 Jan 2023 06:09:04 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Lunsumio (mosunetuzumab-axgb) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy",
        "summary": "Listen to a soundcast of the December 22, 2022, FDA approval of Lunsumio (mosunetuzumab-axgb) for ipatients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.\u201d",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-lunsumio-mosunetuzumab-axgb-adult-patients-relapsed-or",
        "published": "Thu, 19 Jan 2023 10:38:28 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approves updated drug labeling including new indications and dosing regimens for Xeloda (capecitabine) tablets under Project Renewal",
        "summary": "Listen to a soundcast of the December 14, 2022, FDA approval of Xeloda (capecitabine) under Project Renewal, an initiative aimed at updating labeling information for certain older oncology drugs to ensure information is clinically meaningful and scientifically up to date.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approves-updated-drug-labeling-including-new-indications-and-dosing",
        "published": "Tue, 17 Jan 2023 16:21:42 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of  Rezlidhia (olutasidenib) for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation",
        "summary": "Listen to a soundcast of the December 1, 2022, FDA approval of Rezlidhia (olutasidenib) for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-rezlidhia-olutasidenib-relapsed-or-refractory-acute-myeloid",
        "published": "Tue, 10 Jan 2023 10:31:24 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Elahere (mirvetuximab soravtansine-gynx) for FR\u03b1 positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer",
        "summary": "FDA D.I.S.C.O. Burst Edition: FDA approval of Elahere (mirvetuximab soravtansine-gynx) for FR\u03b1 positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-elahere-mirvetuximab-soravtansine-gynx-fra-positive-platinum",
        "published": "Fri, 06 Jan 2023 11:59:30 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approves a new dosing regimen for asparaginase erwinia chrysanthemi (recombinant)",
        "summary": "Listen to a soundcast of the November 18, 2022 FDA approval of a new dosing regimen for asparaginase erwinia chrysanthemi (recombinant).",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approves-new-dosing-regimen-asparaginase-erwinia-chrysanthemi",
        "published": "Wed, 28 Dec 2022 09:39:35 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Adcetris (brentuximab vedotin) in combination with chemotherapy for pediatric patients with classical Hodgkin lymphoma",
        "summary": "FDA D.I.S.C.O. Burst Edition: FDA approval of Adcetris (brentuximab vedotin) in combination with chemotherapy for pediatric patients with classical Hodgkin lymphoma",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-adcetris-brentuximab-vedotin-combination-chemotherapy-pediatric",
        "published": "Thu, 15 Dec 2022 14:08:58 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Libtayo (cemiplimab-rwlc) in combination with platinum-based chemotherapy for non-small cell lung cancer",
        "summary": "Listen to a soundcast of the November 8th 2022  FDA approval of Libtayo (cemiplimab-rwlc) &nbsp;in combination with platinum-based chemotherapy for non-small cell lung cancer",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-libtayo-cemiplimab-rwlc-combination-platinum-based-chemotherapy",
        "published": "Mon, 05 Dec 2022 16:04:34 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy for metastatic non-small cell lung cancer",
        "summary": "Listen to a soundcast of the November 10th 2022 FDA approval of Imjudo (tremelimumab) in combination with Imfinzi (durvalumab)&nbsp;and platinum-based chemotherapy for metastatic non-small cell lung cancer",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-imjudo-tremelimumab-combination-imfinzi-durvalumab-and-platinum",
        "published": "Mon, 05 Dec 2022 10:57:01 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Lytgobi (futibatinib) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene fusions or other rearrangements",
        "summary": "Listen to a soundcast of the 9/30/22 FDA approval of Lytgobi (futibatinib) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene fusions or other rearrangements.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-lytgobi-futibatinib-adult-patients-previously-treated",
        "published": "Wed, 23 Nov 2022 10:59:26 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approvals of Retevmo (selpercatinib) for adult patients with locally advanced or metastatic RET fusion-positive solid tumors, and Retevmo (selpercatinib) for adult patients with locally advanced or metastatic RET fusion-positive non-small cell lung cancer",
        "summary": "Listen to a soundcast of the 9/21/22 FDA approval of Retevmo (selpercatinib) for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection gene fusion that have progressed on or following prior systemic treatment.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-retevmo-selpercatinib-adult-patients-locally-advanced-or",
        "published": "Thu, 03 Nov 2022 11:15:50 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Pedmark (sodium thiosulfate) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month and older with localized, non-metastatic solid tumors",
        "summary": "Listen to a soundcast of the September 20, 2022, the FDA approved sodium thiosulfate (brand name Pedmark) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month and older with localized, non-metastatic solid tumors.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-pedmark-sodium-thiosulfate-reduce-risk-ototoxicity-associated",
        "published": "Wed, 19 Oct 2022 12:36:51 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Imfinzi (durvalumab) for adult patients with locally advanced or metastatic biliary tract cancer",
        "summary": "Listen to a soundcast of the September 2nd, 2022 FDA approval of Imfinzi (durvalumab) for adult patients with locally advanced or metastatic biliary tract cancer.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-imfinzi-durvalumab-adult-patients-locally-advanced-or",
        "published": "Mon, 17 Oct 2022 13:43:41 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Xalkori (crizotinib) for ALK-positive inflammatory myofibroblastic tumor",
        "summary": "Listen to a soundcast of the July 14, 2022 FDA approval of Xalkori (crizotinib) for ALK-positive inflammatory myofibroblastic tumor.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-xalkori-crizotinib-alk-positive-inflammatory-myofibroblastic",
        "published": "Mon, 01 Aug 2022 13:37:15 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for unresectable or metastatic solid tumors with BRAF V600E mutation",
        "summary": "Listen to a soundcast of the June 22nd 2022  FDA approval of Tafinlar (dabrafenib) for in combination w/trametinib (brand name Mekinist) for unresectable or metastatic solid tumors with BRAF V600E mutation.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-tafinlar-dabrafenib-combination-mekinist-trametinib",
        "published": "Mon, 25 Jul 2022 09:32:43 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Breyanzi (lisocabtagene maraleucel) for second-line treatment of large B-cell lymphoma",
        "summary": "FDA D.I.S.C.O. Burst Edition: FDA approval of Breyanzi (lisocabtagene maraleucel) for second-line treatment of large B-cell lymphoma",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-breyanzi-lisocabtagene-maraleucel-second-line-treatment-large-b",
        "published": "Thu, 21 Jul 2022 10:13:22 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Tibsovo (ivosidenib) in combination with azacitidine for newly diagnosed acute myeloid leukemia with a susceptible IDH1 mutation, as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy",
        "summary": "Listen to a soundcast of the 05/25/022, FDA approval of Tibsovo (ivosidenib) for newly diagnosed acute myeloid leukemia with a susceptible IDH1 mutation, as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-tibsovo-ivosidenib-combination-azacitidine-newly-diagnosed",
        "published": "Fri, 17 Jun 2022 14:18:54 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Vidaza (azacitidine) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia",
        "summary": "Listen to a soundcast of the May 20, 2022, the FDA approved azacitidine (brand name Vidaza) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-vidaza-azacitidine-pediatric-patients-newly-diagnosed-juvenile",
        "published": "Fri, 03 Jun 2022 12:40:33 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for adult patients with unresectable or metastatic HER2-positive breast cancer",
        "summary": "Listen to a soundcast of the 5/4/2022 FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for adult patients with unresectable or metastatic HER2-positive breast cancer.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-enhertu-fam-trastuzumab-deruxtecan-nxki-adult-patients",
        "published": "Tue, 24 May 2022 10:37:26 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Vijoice (alpelisib) for adult and pediatric patients two years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum who require systemic therapy",
        "summary": "Listen to a soundcast of the 4/5/2022 FDA approval of Vijoice (alpelisib)  for adult and pediatric patients two years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum who require systemic therapy.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-vijoice-alpelisib-adult-and-pediatric-patients-two-years-age",
        "published": "Wed, 27 Apr 2022 09:38:28 EDT",
        "keywords": [
            "FDA approval",
            "PIK3CA"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval Yescarta (axicabtagene ciloleucel) for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy",
        "summary": "Listen to a soundcast of the April 1st 2022 FDA approval of Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-yescarta-axicabtagene-ciloleucel-adult-patients-large-b-cell",
        "published": "Fri, 22 Apr 2022 06:14:35 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O.: Burst Edition: FDA approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy",
        "summary": "Listen to a soundcast of the March 23, 2022 FDA approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for metastatic castration-resistant prostate cancer",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-pluvicto-lutetium-lu-177-vipivotide-tetraxetan-treatment-adult",
        "published": "Fri, 22 Apr 2022 06:18:35 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of CARVYKTI (ciltacabtagene autoleucel) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody",
        "summary": "Listen to a soundcast of the 2/28/2022 FDA approval of CARVYKTI (ciltacabtagene autoleucel) for the treatment of adults with relapsed or refractory multiple myeloma after 4 or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-carvykti-ciltacabtagene-autoleucel-treatment-adult-patients",
        "published": "Wed, 30 Mar 2022 14:45:52 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma",
        "summary": "Listen to a soundcast of the January 25, 2022 FDA approval of Kimmtrak (tebentafusp-tebn) for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approves-tebentafusp-tebn-unresectable-or-metastatic-uveal-melanoma",
        "published": "Tue, 15 Feb 2022 10:22:35 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Orencia (abatacept) for prophylaxis of acute graft versus host disease",
        "summary": "Listen to a soundcast of the December 15, 2021 FDA approval of Orencia (abatacept) for prophylaxis of acute graft versus host disease.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-orencia-abatacept-prophylaxis-acute-graft-versus-host-disease",
        "published": "Tue, 18 Jan 2022 13:44:18 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound)) for locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor",
        "summary": "Listen to a soundcast of the November 22, 2021, FDA approval of Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound) for locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-fyarro-sirolimus-protein-bound-particles-injectable-suspension",
        "published": "Mon, 06 Dec 2021 13:48:40 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for the adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions",
        "summary": "Listen to a soundcast of the November 17, 2021 FDA approval of Keytruda (pembrolizumab) for the adjuvant treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-keytruda-pembrolizumab-adjuvant-treatment-patients-renal-cell",
        "published": "Wed, 24 Nov 2021 09:18:21 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Scemblix (asciminib) for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with tyrosine kinase inhibitors, and for adult patients in chronic phase with the T315I mutation",
        "summary": "Listen to a soundcast of the October 29, 2021, FDA approval of Scemblix (asciminib) for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with  tyrosine kinase inhibitors, and for adult patients in chronic phase with the T315I mutation",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-scemblix-asciminib-patients-philadelphia-chromosome-positive",
        "published": "Tue, 09 Nov 2021 14:31:09 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Tecentriq (atezolizumab) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer",
        "summary": "Listen to a soundcast of the October 15, 2021 FDA approval of Tecentriq (atezolizumab) for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-tecentriq-atezolizumab-adjuvant-treatment-following-resection",
        "published": "Tue, 26 Oct 2021 06:48:00 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approvals of Verzenio (abemaciclib) for adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer, & Keytruda (pembrolizumab) for persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS\u202f\u22651)",
        "summary": "FDA approvals of Verzenio (abemaciclib) for adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer, &amp; Keytruda (pembrolizumab) for persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS\u202f\u2265",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-verzenio-abemaciclib-adjuvant-treatment-adult-patients-hormone",
        "published": "Mon, 25 Oct 2021 12:18:46 EDT",
        "keywords": [
            "PD-L1"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Tecartus (brexucabtagene autoleucel) for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia",
        "summary": "Listen to a soundcast of the October 1, 2021 FDA approval of Tecartus (brexucabtagene autoleucel) for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-tecartus-brexucabtagene-autoleucel-adult-patients-relapsed-or",
        "published": "Thu, 14 Oct 2021 09:34:46 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Cabometyx (cabozantinib) for locally advanced or metastatic differentiated thyroid cancer",
        "summary": "Listen to a soundcast of the September 17, 2021 FDA approval of Cabometyx (cabozantinib) for locally advanced or metastatic differentiated thyroid cancer.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-cabometyx-cabozantinib-locally-advanced-or-metastatic",
        "published": "Mon, 04 Oct 2021 14:33:58 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Brukinsa (zanubrutinib) for adult patients with Waldenstr\u00f6m\u2019s macroglobulinemia",
        "summary": "Listen to a soundcast of the August 31, 2021 FDA approval of Brukinsa (zanubrutinib) for adult patients with Waldenstr\u00f6m\u2019s macroglobulinemia",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-brukinsa-zanubrutinib-adult-patients-waldenstroms",
        "published": "Wed, 15 Sep 2021 11:57:30 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Tibsovo (ivosidenib) for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test",
        "summary": "Listen to a soundcast of the August 25, 2021 FDA approval of Tibsovo (ivosidenib) for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 mutation as detected by an FDA-approved test",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-tibsovo-ivosidenib-adult-patients-previously-treated-locally",
        "published": "Tue, 07 Sep 2021 13:04:04 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Lenvima (lenvatinib) in combination with Keytruda (pembrolizumab) for first-line treatment of adult patients with advanced renal cell carcinoma",
        "summary": "Listen to a soundcast of the August 10, 2021 FDA approval of Lenvima (lenvatinib) in combination with Keytruda (pembrolizumab) for first-line treatment of adult patients with advanced renal cell carcinoma",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-lenvima-lenvatinib-combination-keytruda-pembrolizumab-first",
        "published": "Wed, 25 Aug 2021 09:50:08 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Welireg (belzutifan) for adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery",
        "summary": "Listen to a soundcast of the August 8, 2021, FDA approval of Welireg (belzutifan) for patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-welireg-belzutifan-adult-patients-von-hippel-lindau-disease-who",
        "published": "Wed, 25 Aug 2021 14:21:31 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for high-risk early-stage triple-negative breast cancer",
        "summary": "Listen to a soundcast of the July 26, 2021 FDA approval of Keytruda (pembrolizumab) for high-risk early-stage triple-negative breast cancer",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-keytruda-pembrolizumab-high-risk-early-stage-triple-negative",
        "published": "Wed, 11 Aug 2021 13:43:25 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) for advanced endometrial carcinoma",
        "summary": "Listen to a soundcast of the July 21, 2021 FDA approval of Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) for advanced endometrial carcinoma",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-keytruda-pembrolizumab-combination-lenvima-lenvatinib-advanced",
        "published": "Fri, 30 Jul 2021 10:47:51 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Rezurok (belumosudil) for adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy",
        "summary": "Listen to a soundcast of the July 16, 2021 FDA approval of Rezurok (belumosudil) for adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-rezurok-belumosudil-adult-and-pediatric-patients-12-years-and",
        "published": "Wed, 28 Jul 2021 11:06:06 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approves Rylaze (asparaginase erwinia chrysanthemi (recombinant) - rywn) for \u200btreatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase",
        "summary": "Listen to a soundcast of the July 1, 2021 FDA approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant) - rywn) for \u200btreatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in patients who have developed hypersensitivity to E. coli-derived asparaginase.\u200b",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approves-rylaze-asparaginase-erwinia-chrysanthemi-recombinant-rywn",
        "published": "Mon, 12 Jul 2021 13:23:50 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Ayvakit (avapritinib) for adult patients with advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia",
        "summary": "Listen to a soundcast of the June 16, 2021 FDA approval of Ayvakit (avapritinib) for adult patients with advanced systemic mastocytosis , including patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm, and mast cell leukemia",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-ayvakit-avapritinib-adult-patients-advanced-systemic",
        "published": "Thu, 24 Jun 2021 12:14:49 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approvals of Lumakras (sotorasib) for patients with KRAS G12C  mutated locally advanced or metastatic non-small cell lung cancer, and Truseltiq (infigratinib) for unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement",
        "summary": "Listen to a soundcast of the May 28, 2021, approvals of Lumakras for patients with KRAS G12C\u2011mutated locally advanced or metastatic non-small cell lung cancer, and Truseltiq for unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-lumakras-sotorasib-patients-kras-g12c-mutated-locally-advanced",
        "published": "Thu, 17 Jun 2021 08:57:39 EDT",
        "keywords": [
            "KRAS"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma",
        "summary": "Listen to a soundcast of the May 5, 2021 FDA approval of Keytruda (pembrolizumab) combined with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of locally advanced unresectable/ metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-keytruda-pembrolizumab-combination-trastuzumab-fluoropyrimidine",
        "published": "Wed, 12 May 2021 12:01:56 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approvals of Trodelvy (sacituzumab govitecan) for locally advanced/metastatic urothelial cancer who received platinum-containing chemotherapy & either PD-1/PD-L1 inhibitor and Opdivo (nivolumab) in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma",
        "summary": "Trodelvy (sacituzumab govitecan) for locally advanced/metastatic urothelial cancer who received platinum-containing chemotherapy &amp; either PD-1/PD-L1 inhibitor. Opdivo (nivolumab) in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-trodelvy-sacituzumab-govitecan-locally-advancedmetastatic",
        "published": "Fri, 23 Apr 2021 13:35:39 EDT",
        "keywords": [
            "PD-L1"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Sarclisa (isatuximab-irfc) in combination with carfilzomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy",
        "summary": "Listen to a soundcast of the March 31, 2021 FDA approval of Sarclisa (isatuximab-irfc) in combination with carfilzomib and dexamethasone for treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-sarclisa-isatuximab-irfc-combination-carfilzomib-and",
        "published": "Tue, 13 Apr 2021 11:13:18 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of ABECMA (idecabtagene vicleucel) the first FDA approved cell-based gene therapy for the treatment of adult patients with relapsed or refractory multiple myeloma",
        "summary": "Listen to a soundcast of the March 26, 2021 FDA approval of ABECMA (idacabtagene vicleucel) the first cell-based gene therapy for treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-abecma-idecabtagene-vicleucel-first-fda-approved-cell-based",
        "published": "Wed, 07 Apr 2021 11:28:49 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for patients with metastatic or locally advanced esophageal or gastroesophageal carcinoma",
        "summary": "FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal carcinoma.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-keytruda-pembrolizumab-patients-metastatic-or-locally-advanced",
        "published": "Mon, 05 Apr 2021 09:06:57 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Fotivda (tivozanib) for adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies",
        "summary": "Listen to a soundcast of the March 10, 2021 FDA approval of Fotivda (tivozanib) for adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-fotivda-tivozanib-adult-patients-relapsed-or-refractory",
        "published": "Wed, 31 Mar 2021 11:46:14 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: Yescarta (axicabtagene ciloleucel) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy",
        "summary": "Listen to a soundcast of the March 5, 2021 FDA approval of Yescarta (axicabtagene ciloleucel) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-yescarta-axicabtagene-ciloleucel-adult-patients-relapsed-or-refractory",
        "published": "Mon, 22 Mar 2021 12:42:17 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst: Approval of Pepaxto (melphalan flufenamide) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four lines of prior therapy",
        "summary": "Listen to a soundcast of the February 26, 2021 FDA approval of Pepaxto (melphalan flufenamide) in combination with dexamethasone for adults patients with refractory multiple myeloma who received at least four prior lines of therapy.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-approval-pepaxto-melphalan-flufenamide-combination-dexamethasone-adult-patients",
        "published": "Tue, 16 Mar 2021 09:38:49 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: Libtayo (cemiplimab-rwlc) for first-line treatment of patients with advanced NSCLC (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high PD-L1 expression with no eGFR, anaplastic lymphoma kinase or receptor tyrosine kinase aberrations",
        "summary": "Listen to a soundcast of the February 22nd 2021 FDA approval of Libtayo (cemiplimab-rwlc) for first-line treatment of patients with advanced NSCLC (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high PD-L1 expression",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-libtayo-cemiplimab-rwlc-first-line-treatment-patients-advanced-nsclc-locally",
        "published": "Fri, 12 Mar 2021 06:01:35 EST",
        "keywords": [
            "FDA approval",
            "PD-L1"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: Breyanzi (lisocabtagene maraleucel)",
        "summary": "Listen to a soundcast of the Feb 5th 2021 FDA approval of Breyanzi for treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-breyanzi-lisocabtagene-maraleucel",
        "published": "Thu, 04 Mar 2021 16:27:30 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O.: FDA approval of Cablivi for acquired thrombotic thrombocytopenic purpura",
        "summary": "FDA medical oncologists discuss the February 6, 2019, approval of caplacizumab-yhdp for acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-fda-approval-cablivi-acquired-thrombotic-thrombocytopenic-purpura",
        "published": "Fri, 12 Apr 2019 13:11:00 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma",
        "summary": "FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma <br />\nFDA medical oncologists discuss the January 14, 2019, approval of cabozantinib for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-fda-approval-cabozantinib-hepatocellular-carcinoma",
        "published": "Tue, 12 Mar 2019 15:05:57 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O.: FDA approval of larotrectinib for advanced malignancies with NTRK gene fusion",
        "summary": "FDA medical oncologists discuss the accelerated approval of larotrectinib for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-fda-approval-larotrectinib-advanced-malignancies-ntrk-gene-fusion",
        "published": "Thu, 13 Dec 2018 14:53:25 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O.: FDA approval of cemiplimab-rwlc for cutaneous squamous cell carcinoma",
        "summary": "FDA medical oncologists discuss the September 28, 2018, approval of cemiplimab-rwlc for the treatment of select patients with cutaneous squamous cell carcinoma.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-fda-approval-cemiplimab-rwlc-cutaneous-squamous-cell-carcinoma",
        "published": "Fri, 30 Nov 2018 13:40:22 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O.: FDA approval of moxetumomab pasudotox-tdfk for relapsed or refractory hairy cell leukemia",
        "summary": "FDA medical oncologists discuss the Sept. 13, 2018, approval of moxetumomab pasudotox-tdfk for the treatment of patients with relapsed or refractory hairy cell leukemia",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-fda-approval-moxetumomab-pasudotox-tdfk-relapsed-or-refractory-hairy-cell-leukemia",
        "published": "Thu, 29 Nov 2018 15:47:58 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA D.I.S.C.O.: First FDA approval of a CAR T-cell immunotherapy",
        "summary": "FDA medical oncologists discuss the first approval of a chimeric antigen receptor (CAR) T-cell immunotherapy.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-first-fda-approval-car-t-cell-immunotherapy",
        "published": "Fri, 23 Feb 2018 11:08:00 EST",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)",
        "summary": "Listen to an audio podcast of the July 26, 2019 FDA Drug Safety Communication on FDA approval of Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR).",
        "link": "http://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and",
        "published": "Mon, 05 Aug 2019 11:01:42 EDT",
        "keywords": [
            "FDA approval"
        ]
    },
    {
        "title": "Natera MRD Study Results Demonstrate Potential to Ressurect Failed Adjuvant Drugs",
        "summary": "<p><span><span><span>The company analyzed MRD status in samples from a prior failed study, showing a significant benefit from the drug for ctDNA-positive patients.</span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/natera-mrd-study-results-demonstrate-potential-ressurect-failed-adjuvant-drugs",
        "published": "Mon, 27 Jan 2025 15:47:45 EST",
        "keywords": [
            "ctDNA"
        ]
    },
    {
        "title": "Natera MRD Study Results Demonstrate Potential to Ressurect Failed Adjuvant Drugs",
        "summary": "<p><span><span><span>The company analyzed MRD status in samples from a prior failed study, showing a significant benefit from the drug for ctDNA-positive patients.</span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/natera-mrd-study-results-demonstrate-potential-ressurect-failed-adjuvant-drugs",
        "published": "Mon, 27 Jan 2025 15:47:45 EST",
        "keywords": [
            "ctDNA"
        ]
    },
    {
        "title": "Natera MRD Study Results Demonstrate Potential to Ressurect Failed Adjuvant Drugs",
        "summary": "<p><span><span><span>The company analyzed MRD status in samples from a prior failed study, showing a significant benefit from the drug for ctDNA-positive patients.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/natera-mrd-study-results-demonstrate-potential-ressurect-failed-adjuvant-drugs",
        "published": "Mon, 27 Jan 2025 15:47:45 EST",
        "keywords": [
            "ctDNA"
        ]
    },
    {
        "title": "Natera MRD Study Results Demonstrate Potential to Ressurect Failed Adjuvant Drugs",
        "summary": "<p><span><span><span>The company analyzed MRD status in samples from a prior failed study, showing a significant benefit from the drug for ctDNA-positive patients.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/natera-mrd-study-results-demonstrate-potential-ressurect-failed-adjuvant-drugs",
        "published": "Mon, 27 Jan 2025 15:47:45 EST",
        "keywords": [
            "ctDNA"
        ]
    },
    {
        "title": "Data From TRACERx Study Boosts Evidence for Personalis' MRD Test Performance in Lung Cancer",
        "summary": "<p><span><span><span>The retrospective results suggest that the test's sensitivity boost over other platforms can overcome the challenge of detecting ctDNA in adenocarcinomas.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/data-tracerx-study-boosts-evidence-personalis-mrd-test-performance-lung-cancer",
        "published": "Thu, 16 Jan 2025 14:52:17 EST",
        "keywords": [
            "ctDNA"
        ]
    }
]